BioWorld

Jan. 3, 2006

Genentech Submits Lucentis BLA For Age-Related AMD

Ever on the march, Genentech Inc. rounded out the year with another regulatory move, submitting - as promised - a biologics license application for Lucentis against neovascular wet age-related macular degeneration. (BioWorld Today) Read More

Vanda Seeking $75M IPO For CNS Drug Development

Study Finds Possibly Better Approach To Cox-2 Inhibition

Lawyers Do Not Expect New Curbs On Drug Advertising

Holiday Notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...